References 1. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1997;89:1763-1773. 2. Bruera E. Anorexia, cachexia and nutrition. Br Med J 1997;315:1219-1222. 3. Larkin M. Thwarting the dwindling progression of cachexia. Lancet 1998;351:1336. 4. Inui A. Cancer anorexia-cachexia syndrome: Are neuropeptides the key? Cancer Res 1999; 59:4493-4501. 5. Kotler DP. Cachexia. Ann Intern Med 2000;133:622-634. 6. Barber MD, Ross JA, Fearon KC. Cancer cachexia. Surg Oncol 1999;8:133-141. 7. Davis MP, Dickerson D. Cachexia and anorexia: Cancer’s covert killer. Support Care Cancer 2000;8:180-187. 8. Billingsley KG, Alexander HR. The pathophysiology of cachexia in advanced cancer and AIDS. In: Bruera E, Higginson I, eds. Cachexia-anorexia in cancer patients. Oxford, England: Oxford University Press;1996:1-22. 9. Fearon KC, Barber MD, Falconer JS, et al. Pancreatic cancer as a model: Inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg 1999;23:584-588. 10. Higginson I, Bruera, E. Practical concepts for clinicians. In: Bruera E, Higginson I, eds. Cachexia-anorexia in cancer patients. Oxford, England: Oxford University Press;1996:185-189. 11. Burman R, Chamberlain J. The assessment of the nutritional status, caloric intake, and appetite of patients with advanced cancer. In: Bruera E, Higginson I, eds. Cachexia-anorexia in cancer patients. Oxford, England: Oxford University Press;1996:83-93. 12. Rosenbaum K, Wang J, Pierson RN, Jr., et al. Time-dependent variation in weight and body composition in healthy adults. JPEN J Parenter Enteral Nutr 2000;24:52-55. 13. Moore FD, Olesen KH, McMurray JD, et al. The Body Cell Mass and Its Supporting Environment. Philadelphia, PA: WB Saunders, 1963. 14. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69:491-497. 15. Staal-van den Brekel AJ, Schols AM, ten Velde GP, et al. Analysis of the energy balance in lung cancer patients. Cancer Res 1994;54:6430-6433. 16. Wigmore SJ, Plester CE, Ross JA, et al. Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. Br J Surg 1997;84:196-197. 17. Flier JS. Clinical review 94: What’s in a name? In search of leptin’s physiologic role. J Clin Endocrinol Metab 1998;83:1407-1413. 18. Schwartz MW, Dallman MF, Woods SC. Hypothalamic response to starvation: Implications for the study of wasting disorders. Am J Physiol 1995;269:949-957. 19. Schwartz MW, Seeley RJ. Neuroendocrine responses to starvation and weight loss. N Engl J Med 1997;336:1802-1811. 20. Inui A. Feeding and body-weight regulation by hypothalamic neuropeptides—mediation of the actions of leptin. Trends Neurosci 1999;22:62-67. 21. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763-770. 22. Elmquist JK, Maratos-Flier E, Saper CB, et al. Unraveling the central nervous system pathways underlying responses to leptin. Nat Neurosci 1998;1:445-450. 23. Woods SC, Seeley RJ, Porte D, Jr., et al. Signals that regulate food intake and energy homeostasis. Science 1998;280:1378-1383. 24. Bray GA, York DA. The MONA LISA hypothesis in the time of leptin. Recent Prog Horm Res 1998;53:95-117. 25. Kalra SP, Dube MG, Pu S, et al. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999;20:68-100. 26. Schwartz MW, Woods SC, Porte D, Jr., et al. Central nervous system control of food intake. Nature 2000;404:661-671. 27. Inui A. Transgenic approach to the study of body weight regulation. Pharmacol Rev 2000;52:35-61. 28. Inui A. Transgenic study of energy homeostasis equation: Implications and confounding influences. Faseb J 2000;14:2158-2170. 29. Moldawer LL, Copeland EM, 3rd. Proinflammatory cytokines, nutritional support, and the cachexia syndrome: Interactions and therapeutic options. Cancer 1997;79:1828-1839. 30. Haslett PA. Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 1998;25:53-57. 31. Mantovani G, Maccio A, Lai P, et al. Cytokine activity in cancer-related anorexia/cachexia: Role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 1998;25:45-52. 32. Inui A. Neuropeptide Y: A key molecule in anorexia and cachexia in wasting disorders? Mol Med Today 1999;5:79-85. 33. MacDonald N. Cachexia-anorexia workshop: Introduction. Nutrition 2000;16:1007-1008. 34. Plata-Salaman CR. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition 2000;16:1009-1012. 35. Tisdale MJ. Metabolic abnormalities in cachexia and anorexia. Nutrition 2000;16:1013-1014. 36. Baracos VE. Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia. Nutrition 2000;16:1015-1018. 37. MacDonald N. Workshop summary and conclusions. Nutrition 2000;16:1019-1020. 38. Moldawer LL, Rogy MA, Lowry SF. The role of cytokines in cancer cachexia. JPEN J Parenter Enteral Nutr 1992;16:43-49. 39. Noguchi Y, Yoshikawa T, Matsumoto A, et al. Are cytokines possible mediators of cancer cachexia? Surg Today 1996;26:467-475. 40. Matthys P, Billiau A. Cytokines and cachexia. Nutrition 1997;13:763-770. 41. Gelin J, Moldawer LL, Lonnroth C, et al. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res 1991;51:415-421. 42. Chance WT, Balasubramaniam A, Thompson H, et al. Assessment of feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y. Peptides 1996;17:797-801. 43. Chance WT, Balasubramaniam A, Dayal R, et al. Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumor-bearing rats. Life Sci 1994;54:1869-1874. 44. McCarthy HD, McKibbin PE, Perkins AV, et al. Alterations in hypothalamic NPY and CRF in anorexic tumor-bearing rats. Am J Physiol 1993;264:638-643. 45. Sonti G, Ilyin SE, Plata-Salaman CR. Neuropeptide Y blocks and reverses interleukin-1b-induced anorexia in rats. Peptides 1996; 17:517-520. 46. Gayle D, Ilyin SE, Plata-Salaman CR. Central nervous system IL-1b system and neuropeptide Y mRNA during IL-1b-induced anorexia in rats. Brain Res Bull 1997;44:311-317. 47. Sonti G, Ilyin SE, Plata-Salaman CR. Anorexia induced by cytokine interactions at pathophysiological concentrations. Am J Physiol 1996;270:1349-1402. 48. Jensen PB, Blume N, Mikkelsen JD, et al. Transplantable rat glucagonomas cause acute onset of severe anorexia and adipsia despite highly elevated NPY mRNA levels in the hypothalamic arcuate nucleus. J Clin Invest 1998;101:503-510. 49. Plata-Salaman CR, Ilyin SE, Gayle D. Brain cytokine mRNAs in anorectic rats bearing prostate adenocarcinoma tumor cells. Am J Physiol 1998;275:566-573. 50. Marks DL, Ling N, Cone RD. Role of the central melanocortin system in cachexia. Cancer Res 2001;61:1432-1438. 51. Wisse BE, Frayo RS, Schwartz MW, et al. Reversal of Cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001;142:3292-3301. 52. Lechan RM, Tatro JB. Hypothalamic melanocortin signaling in cachexia. Endocrinology 2001;142:3288-3291. 53. Nelson KA, Walsh D, Sheehan FA. The cancer anorexia-cachexia syndrome. J Clin Oncol 1994;12:213-225. 54. Glaus A. Fatigue and cachexia in cancer patients. Support Care Cancer 1998;6:77-78. 55. Bessesen DH, Faggioni R. Recently identified peptides involved in the regulation of body weight. Semin Oncol 1998;25:28-32. 56. Tayek JA. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 1992;11:445-456. 57. Hirai K, Hussey HJ, Barber MD, et al. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 1998;58:2359-2365. 58. Tisdale MJ. Cancer anorexia and cachexia. Nutrition 2001;17:438-442. 59. Nixon DW, Heymsfield SB, Cohen AE, et al. Protein-calorie undernutrition in hospitalized cancer patients. Am J Med 1980;68:683-690. 60. Lundholm K, Bylund AC, Holm J, et al. Skeletal muscle metabolism in patients with malignant tumor. Eur J Cancer 1976;12:465-473. 61. Jeevanandam M, Horowitz GD, Lowry SF, et al. Cancer cachexia and protein metabolism. Lancet 1984;1:1423-1426. 62. Falconer JS, Fearon KC, Ross JA, et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995;75: 2077-2082. 63. Staal-van den Brekel AJ, Dentener MA, Schols AM, et al. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 1995;13:2600-2605. 64. Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 1992;52:3317-3322. 65. Reeds PJ, Fjeld CR, Jahoor F. Do the differences between the amino acid compositions of acute-phase and muscle proteins have a bearing on nitrogen loss in traumatic states? J Nutr 1994;124:906-910. 66. Belizario JE, Katz M, Chenker E, et al. Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma proteins from cancer patients with weight loss. Br J Cancer 1991;63:705-710. 67. Smith KL, Tisdale MJ. Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia. Br J Cancer 1993;67:680-685. 68. Todorov P, Cariuk P, McDevitt T, et al. Characterization of a cancer cachectic factor. Nature 1996;379:739-742. 69. Tisdale MJ. Protein loss in cancer cachexia. Science 2000;289:2293-2294. 70. Guttridge DC, Mayo MW, Madrid LV, et al. NF-kB-induced loss of MyoD messenger RNA: Possible role in muscle decay and cachexia. Science 2000;289:2363-2366. 71. Nitenberg G, Raynard B. Nutritional support of the cancer patient: Issues and dilemmas. Crit Rev Oncol Hematol 2000;34:137-168. 72. DeWys WD. Anorexia as a general effect of cancer. Cancer 1979;43:2013-2019. 73. DeWys WD, Walters K. Abnormalities of taste sensation in cancer patients. Cancer 1975;36:1888-1896. 74. Bernstein IL. Learned taste aversions in children receiving chemotherapy. Science 1978;200: 1302-1303. 75. Glass MJ, Billington CJ, Levine AS. Opioids and food intake: Distributed functional neural pathways? Neuropeptides 1999;33:360-368. 76. Fujimiya M, Inui A. Peptidergic regulation of gastrointestinal motility in rodents. Peptides 2000;21:1565-1582. 77. Tache Y, Garrick T, Raybould H. Central nervous system action of peptides to influence gastrointestinal motor function. Gastroenterology 1990;98:517-528. 78. Inui A, Okano H, Miyamoto M, et al. Delayed gastric emptying in bulimic patients. Lancet 1995;346:1240. 79. Okano H, Inui A, Ueno N, et al. EM523L, a nonpeptide motilin agonist, stimulates gastric emptying and pancreatic polypeptide secretion. Peptides 1996;17:895-900. 80. Mitchell EP. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol 1992;19:566-579. 81. Body JJ. Metabolic sequelae of cancers (excluding bone marrow transplantation). Curr Opin Clin Nutr Metab Care 1999;2:339-344. 82. Body JJ. The syndrome of anorexia-cachexia. Curr Opin Oncol 1999;11:255-260. 83. Klein S, Kinney J, Jeejeebhoy K, et al. Nutrition support in clinical practice: Review of published data and recommendations for future research directions. Am J Clin Nutr 1997;66: 683-706. 84. Sikora SS, Ribeiro U, Kane JM, III., et al. Role of nutrition support during induction chemoradiation therapy in esophageal cancer. JPEN J Parenter Enteral Nutr 1998;22:18-21. 85. Miller M. Can reducing caloric intake also help reduce cancer? J Natl Cancer Inst 1998;90:1766-1767. 86. Nelson KA. The cancer anorexia-cachexia syndrome. Semin Oncol 2000;27:64-68. 87. Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs 1998;55:675-688. 88. Argiles JM, Meijsing SH, Pallares-Trujillo J, et al. Cancer cachexia: A therapeutic approach. Med Res Rev 2001;21:83-101. 89. Bruera E. Pharmacological treatment of cachexia: Any progress? Support Care Cancer 1998;6:109-113. 90. Fainsinger R. Pharmacological approach to cancer anorexia and cachexia. In: Bruera E, Higginson I, eds. Cachexia-anorexia in cancer patients. Oxford, England: Oxford University Press;1996:128-140. 91. Mantovani G, Maccio A, Massa E, et al. Managing cancer-related anorexia / cachexia. Drugs 2001;61:499-514. 92. Moertel CG, Schutt AJ, Reitemeier RJ, et al. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974;33:1607-1609. 93. Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: A prospective randomized double-blind study. Cancer Treat Rep 1985;69:751-754. 94. Popiera T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol 1989;25:1823-1829. 95. Willox JC, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer. Br Med J 1984;288:27. 96. Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990;82:1127-1132. 97. Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993;11:762-767. 98. Bruera E, Macmillan K, Kuehn N, et al. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990;66:1279-1282. 99. Feliu J, Gonzalez-Baron M, Berrocal A, et al. Treatment of cancer anorexia with megestrol acetate: Which is the optimal dose? J Natl Cancer Inst 1991;83:449-450. 100. Tchekmedyian NS, Hickman M, Siau J, et al. Megestrol acetate in cancer anorexia and weight loss. Cancer 1992;69:1268-1274. 101. Loprinzi CL, Schaid DJ, Dose AM, et al. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993;11:152-154. 102. Rowland KM Jr, Loprinzi CL, Shaw EG, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: A North Central Cancer Treatment Group study. J Clin Oncol 1996;14:135-141. 103. Ottery FD, Walsh D, Strawford A. Pharmacologic management of anorexia/cachexia. Semin Oncol 1998;25:35-44. 104. Maltoni M, Nanni O, Scarpi E, et al. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: A systemic review of randomized clinical trials. Ann Oncol 2001;12:289-300. 105. McCarthy HD, Crowder RE, Dryden S, et al. Megestrol acetate stimulates food intake in the rat: Effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol 1994;265:99-102. 106. Costa AM, Spence KT, Plata-Salaman CR, et al. Residual Ca2+ channel current modulation by megestrol acetate via a G-protein alpha s-subunit in rat hypothalamic neurons. J Physiol 1995;487:291-303. 107. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990;65:2657-2662. 108. Meguid MM, Fetissov SO, Varma M, et al. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 2000;16:843-857. 109. Laviano A, Meguid MM, Yang ZJ, et al. Cracking the riddle of cancer anorexia. Nutrition 1996;12:706-710. 110. Moertel CG, Kvols LK, Rubin J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 1991;67:33-36. 111. Edelman MJ, Gandara DR, Meyers FJ, et al. Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. Cancer 1999;86:684-688. 112. Tayek JA, Bistrian BR, Hehir DJ, et al. Improved protein kinetics and albumin synthesis by branched chain amino acid-enriched total parenteral nutrition in cancer cachexia. A prospective randomized crossover trial. Cancer 1986;58:147-157. 113. Cangiano C, Laviano A, Meguid MM, et al. Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. J Natl Cancer Inst 1996;88: 550-552. 114. Pereira J, Bruera E. Chronic nausea. In: Bruera E, Higginson I, eds. Cachexia-anorexia in cancer patients. Oxford, England: Oxford University Press;1996:23-37. 115. Bruera ED, MacEachern TJ, Spachynski KA, et al. Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer 1994;74:3204-3211. 116. Beck SA, Smith KL, Tisdale MJ. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 1991;51:6089-6093. 117. Tisdale MJ. Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia. Nutrition 1996;12:31-33. 118. Wigmore SJ, Ross JA, Falconer JS, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996;12:27-30. 119. Wigmore SJ, Fearon KC, Maingay JP, et al. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci 1997;92:215-221. 120. Barber MD, Ross JA, Voss AC, et al. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 1999;81:80-86. 121. Gogos CA, Ginopoulos P, Salsa B, et al. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: A randomized control trial. Cancer 1998;82:395-402. 122. Nelson K, Walsh D, Deeter P, et al. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 1994;10:14-18. 123. Plasse TF, Gorter RW, Krasnow SH, et al. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991;40:695-700. 124. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822-825. 125. Tanaka Y, Eda H, Fujimoto K, et al. Anticachectic activity of 5'-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res 1990;50:4528-4532. 126. Hussey HJ, Todorov PT, Field WN, et al. Effect of a fluorinated pyrimidine on cachexia and tumor growth in murine cachexia models: Relationship with a proteolysis inducing factor. Br J Cancer 2000;83:56-62. 127. Tohgo A, Kumazawa E, Wagai N, et al. Anti-cancer drugs affect cancer anorexia and cachexia. Expert Review of Anticancer Therapy. In press. 128. Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996;32:1340-1343. 129. Lissoni P, Paolorossi F, Ardizzoia A, et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res 1997;23:15-19. 130. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:247-257. 131. Bruera E, Neumann CM, Pituskin E, et al. Thalidomide in patients with cachexia due to terminal cancer: Preliminary report. Ann Oncol 1999;10:857-859. 132. D’Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-4085. 133. Costelli P, Garcia-Martinez C, Llovera M, et al. Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest 1995;95:2367-2372. 134. Maltin CA, Delday MI, Watson JS, et al. Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin Sci 1993;84:651-654. 135. McMillan DC, Leen E, Smith J, et al. Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol 1995;21:531-534. 136. Preston T, Fearon KC, McMillan DC, et al. Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss. Br J Surg 1995;82:229-234. 137. Wigmore SJ, Falconer JS, Plester CE, et al. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. Br J Cancer 1995;72:185-188. 138. McMillan DC, Wigmore SJ, Fearon KC, et al. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999;79:495-500. 139. Lundholm K, Gelin J, Hyltander A, et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994;54:5602-5606. 140. Inui A. Cytokine and sickness behavior: Implications from knockout animal models. Trends Immunol;22:469-473. 141. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311. 142. Goldberg RM, Loprinzi CL, Mailliard JA, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995;13:2856-2859. 143. Loprinzi CL, Kuross SA, O’Fallon JR, et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 1994;12:1121-1125. 144. Loprinzi CL, Goldberg RM, Su JQ, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 1994;12:1126-1129. 145. Kosty MP, Fleishman SB, Herndon JE 2nd, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: A randomized placebo-controlled, double-blind phase III study of the cancer and leukemia Group B. J Clin Oncol 1994;12:1113-1120. 146. Chlebowski R, Herrold J, Ali I, et al. Influence of nadrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 1986;58:183-186. 147. Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999;17:3299-3306. 148. Whitman MM. The starving patient: Supportive care for people with cancer. Clin J Oncol Nurs 2000;4:121-125. 149. Tait NS. Anorexia-cachexia syndrome. In: Groenwald SL, Goodman M, Frogge MH, Yarbro CH, eds. Cancer symptom management. Boston, MA: Jones and Bartlett Publishers;1996:171-185. 150. Higginson I, Winget C. Psychological impact of cancer cachexia on the patient and family. In: Bruera E, Higginson I, eds. Cachexia-anorexia in cancer patients. Oxford, England: Oxford University Press; 1996:172-183. 151. Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996;18:250-252. 152. Asakawa A, Inui A, Kaga T, et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 2001;120:337-345. 153. Inui A. Ghrelin. An orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci 2001;2:551-560. 154. Goldberg RM, Loprinzi CL. Cancer anorexia/cachexia. In: von Gunten CF, ed. Palliative care and rehabilitation of cancer patients. Boston, MA: Kluwer Academic Publishers;1999:31-34. CA Cancer J Clin 2002;52:72-91 Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.